Table 11 IIncidence of death compared to various factors
From: Risk factors affecting outcome of rhino-orbital-cerebral mucormycosis in COVID-19 patients
| Â | No death | Death | Test value | p-value | Sig. |
|---|---|---|---|---|---|
No. = 24 | No. = 9 | ||||
CT PNS | |||||
 Rt max. S | 12 (50.0%) | 4 (44.4%) | 0.081* | 0.776 | NS |
 Lt max. S | 18 (75.0%) | 8 (88.9%) | 0.755* | 0.385 | NS |
 Rt ethmoid | 15 (62.5%) | 5 (55.6%) | 0.132* | 0.716 | NS |
 Lt ethmoids | 19 (79.2%) | 8 (88.9%) | 0.416* | 0.519 | NS |
 Rt sphenoid | 14 (58.3%) | 5 (55.6%) | 0.021* | 0.886 | NS |
 Lt sphenoid | 18 (75.0%) | 6 (66.7%) | 0.229* | 0.632 | NS |
 Rt frontal | 9 (37.5%) | 4 (44.4%) | 0.132* | 0.716 | NS |
 Lt frontal | 12 (50.0%) | 3 (33.3%) | 0.733* | 0.392 | NS |
 Bony erosions | 13 (54.2%) | 4 (44.4%) | 0.248* | 0.619 | NS |
 Bilateral involvement | 10 (41.7%) | 4 (44.4%) | 0.021* | 0.886 | NS |
COVID status | |||||
 Previous COVID | 17 (70.8%) | 5 (55.6%) | 0.688* | 0.407 | NS |
 PCR at presentation | 3 (12.5%) | 3 (33.3%) | 1.910* | 0.167 | NS |
CT CO-RAD score | |||||
 Median (IQR) | 2 (1–3) | 3.5 (2.5–4.5) | −1.951≠| 0.051 | NS |
 Range | 1–5 | 1–5 | |||
Duration between COVID-19 infection and start of mucormycosis | |||||
 Median (IQR) | 30 (21–60) | 30 (14–45) | −0.355≠| 0.723 | NS |
 Range | 7–90 | 14–80 | |||
Steroids use | 20 ( 83%) | 9 (100%) | 0.001* | 0.001 | HS |
Anti-IL-6 actemra (tocilizumab) | 4 (16.7%) | 2 (22.2%) | 0.136* | 0.712 | NS |
Antiviral (remdesivir) | 4 (16.7%) | 2 (22.2%) | 0.136* | 0.712 | NS |